GlassScriptPhysician profile
Russell Babbitt
NPI 1952416000
$3,783.76
in general payments reported to CMS, 2019-2025
11 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $35.64 · 2021: $58.75 · 2022: $62.41 · 2023: $245 · 2024: $2,735 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,987 · Food and Beverage: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,986.90 |
| Food and Beverage | $1,491.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,234.09 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| Mentor Worldwide LLC | $201.25 | 2019-2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Allergan, INC. | $109.22 | 2019-2022 | |
| Convatec INC. | $59.97 | 2025 | |
| Smith+Nephew, INC. | $40.08 | 2025 | Pico |
| Integra Lifesciences Corporation | $35.64 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.75 | 2023 | Entyvio |
| Revance Therapeutics, INC. | $22.16 | 2025 | Daxxify |
| Kci USA, INC. | $22.13 | 2021 | |
| Davol INC. | $18.78 | 2022 | |
| Solventum Corporation | $13.69 | 2024 | Prevena, Prevena Restor Bellaform |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Babbitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.